

ACCP Foundation Recognizes 2023 Donors



The ACCP Foundation sincerely thanks all 2023 Frontiers Fund donors.

Diamond Donors (\$2500 or more)

Adult Medicine PRN	Infectious Diseases PRN
Bradley A. Boucher	Mary Lee
Cardiology PRN	Michael and Susan Maddux
Lawrence J. Cohen	John E. Murphy
Critical Care PRN	Pediatrics PRN
Ronald Evens	Eva Vasquez
Sheldon G. Holstad	

Platinum Donors (\$1000–\$2499)

Ambulatory Care PRN	Peter Dorson
Julie Banderas	Brian L. Erstad
Jerry Bauman	B. Joseph Guglielmo
Elias B. Chahine	Judi Jacobi and Jim Mowry
Clinical Administration PRN	Robert Parker
Joseph T. and Cecily R. DiPiro	Leigh Ann and Brendan Ross
Amy C. Donihi	James Tisdale

Gold Donors (\$500–\$999)

Sarah E. Bova	GI/Liver/Nutrition PRN
Marcia L. Buck	Melanie R. Madorsky
Judy Cheng	J. Herbert Patterson
Jennifer N. Clements	Pharmaceutical Industry PRN
M. Lynn Crismon	Nancy L. Shapiro
Robert and Julia Elenbaas	Kathleen Stringer
Endocrine and Metabolism PRN	Peter H. Vlasses
Elizabeth A. Farrington	Gary C. Yee
Geriatrics PRN	

Silver Donors (\$100–\$499)

Titilola M. Afolabi	Nitish Bangalore
John M. Allen	David S. Bateshansky
Sarah Amering	Jeffrey Bishop
Melissa Badowski	Melissa M. Blair

Scott Bolesta
 Brandon and Nicole Bookstaver
 Amie Brooks
 James Bustrack
 Barry L. Carter
 Larisa Cavallari
 Lingtak-Neander Chan
 Jennifer Chang
 Allison Chung
 Yoshimi Clark
 Community-Based PRN
 Stephanie M. Crist
 Stephen Dahl
 Andrew Donnelly
 Henry Dunnenberger
 Education and Training PRN
 Erika J. Ernst
 Michelle Fravel
 Kevin W. Garey
 Adam Gummersheimer
 Tracy M. Hagemann
 Karen P. Hansen
 Jimmi Hatton Kolpek
 Brian Hemstreet
 James D. Hoehns
 Joanna Hudson

Bronze Donors (up to \$99)

Christy Adams
 Debra J. Barnette
 Cynthia A. Brasher
 Gayle and Daniel Brazeau
 Gretchen L. Brummel
 Maya Campara
 Eun Kyoung Chung
 Mariann Churchwell
 Christina Cox
 C. Lindsay DeVane
 Chris and Molly Droege
 Shelly Enders
 Sonia S. Everhart

Craig Lee
 Qing Ma
 Patricia Masters
 Linda McCorkill
 Gene Morse and Kathleen Tornatore
 Suzanne Nesbit
 Mary Beth O'Connell
 Keith M. Olsen
 Outcomes and Economics PRN
 Shi-Hui Pan
 Mary Parker
 Perioperative Care PRN
 Hanna Phan
 Edward Pickett
 Pulmonary PRN
 Denise H. Rhoney
 Jo Ellen Rodgers
 Wendy L. St. Peter
 Farida Samarou
 Marc Scheetz
 Terry L. Seaton
 Keri Sims
 Katherine P. Smith
 Barbara Wells
 Nathan Wiederhold

Jon Poynter
Beth H. Resman-Targoff
Mark Newnham
and Marisel
Segarra-Newnham
Jeri Sias
Carmen B. Smith
Sarah A. Spinler
Pamela L. Stamm
Elizabeth Stone

Kayla R. Stover
Brandon and Allana Sucher
Kimberly Thrasher
Lindsey Toman
Brian Trevarrow
Jennifer Trofe-Clark
Lai Fan Jennie Vong
Craig Williams
Kimberly Zammit

ACCP Foundation Awards \$300,000 to Advance Medication Optimization



The ACCP Foundation is pleased to announce awardees for its Medication Optimization Improving Human Health request for applications. This funding opportunity was focused on novel and innovative patient-centered and team-based approaches that may be employed by clinical pharmacists to achieve medication optimization. Each investigative team was awarded \$100,000 to support their work.

OPTOCS AI: Optimizing Pharmacy Transition of Care Services Using Artificial Intelligence




Mohammad Abdulla Al-Mamun, Ph.D.,
Assistant Professor, Pharmaceutical
Systems & Policy
University of West Virginia, School of
Pharmacy
Morgantown, West Virginia



Todd N. Brothers, Pharm.D., BCCCP,
BCPS
Clinical Assistant Professor of Pharmacy
Practice
University of Rhode Island, College of
Pharmacy
Kingston, Rhode Island

OPTI-HEART: Optimizing Medications for Health Equity During Admission and Care Transitions



Katherine Di Palo, Pharm.D., MBA, MS
Senior Director of Transitional Care
Excellence
Montefiore Medical Center
Bronx, New York



Ladan Golestaneh, MD, MS
Professor of Medicine, Division of
Nephrology
Albert Einstein College of Medicine
Bronx, New York

Medication Optimization in Patients with Chronic Kidney Disease with or without Type 2 Diabetes or Heart Failure to Improve Patient-Centered Health Outcomes



Wendy L. St. Peter, Pharm.D., FCCP,
FASN, FNKF
Professor, Pharmaceutical Care &
Health Systems
University of Minnesota, College of
Pharmacy
Minneapolis, Minnesota



Joshua J. Neumiller, Pharm.D., CDCES,
FADCES, FASCP
Professor of Pharmacotherapy
Washington State University, College of
Pharmacy

A request for letters of intent to apply for this funding mechanism was issued by the ACCP Foundation on May 26, 2023, and letters of intent were accepted through July 14. A total of 55 letters were received and then screened to determine whether they met the eligibility criteria and minimum qualifications. Thirty-two applicants were invited to submit full proposals on August 11. Full proposals were due on or before October 31 and a total of 29 were received.

The Foundation is grateful to the grant review panels and funding committee members: Julie Banderas, Jeff Bishop, Amie Brooks, Nicholas Carris, Jaclyn Cusumano, Mark Dunnenberger, Jonathan Hughes, Mary Lee, Mary McClurg, Shawn McFarland, Terry Seaton, Christina Sherrill, Todd Sorensen, Kathleen Stringer, Robert Parker, P. David Rogers, and Eva Vasquez.

The Future of the NIH COVID-19 Treatment Guidelines

ACCP Recognizes Pharmacist Contributors

In response to the rapidly evolving COVID-19 pandemic, the National Institutes of Health assembled a panel of experts (the Panel), including physicians, biostatisticians, clinical pharmacists, and other experts, to provide

practical recommendations for health care providers and issued the first version of the [COVID-19 Treatment Guidelines](#) on April 21, 2020. For close to 4 years, the Panel has critically reviewed the growing body of research data on COVID-19 and used that information to develop and revise their recommendations for treating patients with this disease.

Many pharmacists have made significant contributions to the Panel:

- Pamela Belperio, Pharm.D., BCPS – Department of Veterans Affairs
- Sarita Boyd, Pharm.D. – Food and Drug Administration
- Page Crew, Pharm.D., MPH – Food and Drug Administration
- Susan L. Davis, Pharm.D., FIDP – Wayne State University, Henry Ford Health System
- Amy L. Dzierba, Pharm.D., FCCM, FCCP, BCCCP – New York-Presbyterian Hospital
- Gregory Eschenauer, Pharm.D. – University of Michigan
- Jomy George, Pharm.D. – National Institutes of Health
- Steve Grapentine, Pharm.D. – UCSF Benioff Children's Hospital San Francisco
- Safia Kuriakose, Pharm.D. – NIAID – Assistant Executive Secretary of the Panel
- Christine Macbrayne, Pharm.D., MSCS – Children's Hospital Colorado
- Alice K. Pau, Pharm.D. – National Institutes of Health – Executive Secretary of the Panel
- Kimberly Scarsi, Pharm.D. – University of Nebraska Medical Center

Several members were tasked with developing drug-drug interaction guidance for the use of ritonavir-boosted nirmatrelvir. This page of the guidelines has been the most viewed section of the guidelines since it was released in December 2021, with over 2.6 million page views to date.

The federal COVID-19 Public Health Emergency ended in May 2023. The last update of the guidelines will be published in early 2024. The [guidelines website](#) will remain available for several months following the final update and will provide a downloadable version of the final publication.

2023 Update to GTMRx CMM Evidence Document Now Available



The [Get the Medications Right \(GTMRx\) Institute](#) recently announced the release of the latest edition of its summary of published research from practice sites using comprehensive medication management (CMM). [The Outcomes of Implementing and Integrating Comprehensive Medication Management in Team-Based Care: A Review of the Evidence on Quality, Access and Costs, December 2023](#), commonly referred to as the evidence document, highlights studies published from 2014 through the end of 2023 that best demonstrate the value of CMM in achieving all five aspects of the quintuple aim for health care improvement: providing high-quality care, reducing health care-related costs, improving the patient's care experience, improving health care team members' work-life balance, and achieving health equity.

The 2023 evidence document includes 21 studies, with three published in 2023. The new additions include a paper demonstrating the value of implementing CMM after discharge on readmission and health care costs for patients receiving high-risk medications, an assessment of patient acceptance of CMM in the Veterans Health Administration, and a descriptive report of the impact of CMM in patients with substance use disorder. The updated introduction also includes citations for two important reviews on the potential role for CMM in addressing social determinants of health. As a resource for disseminating the value of CMM, the annual updates of the evidence document continue to reflect the maturation of research in this area and the expansion of CMM into a wider range of practice settings. By sharing the evidence document with health care providers, administrators, and payers, GTMRx serves as an important partner for ACCP in driving the implementation of CMM in team-based patient care. In addition, it is hoped that this edition will stimulate new research demonstrating the value of CMM in reducing the adverse impact of social determinants of health and promoting health equity.

The evidence document is a product of the Evidence-Based Resources Subgroup of the GTMRx Practice and Care Delivery Transformation Workgroup. Authors include Shawn McFarland, Pharm.D., FCCP, BCACP; Marcia Buck, Pharm.D., FCCP, FPPA, BCPPS; Judith Jacobi, Pharm.D., FCCP, MCCM, BCCCP; and Mary Ann Kliethermes, Pharm.D., FAPhA, FCIOM, all members of ACCP. The Practice and Care Delivery Transformation Workgroup, as well as the other GTMRx workgroups, continues to add new members. ACCP members who are interested in participating in GTMRx are encouraged to [become a signing member](#) and indicate their interest in volunteering for a workgroup.

Call for Nominations

All nomination materials, including letters, curricula vitae or resumes, and other supporting documents, can be submitted online to ACCP. For all awards and honors, the College strongly urges nomination of qualified individuals who identify as members of underrepresented groups in ACCP. The online nominations portal specifies the nominating materials required for each award, honor, and elective office. This portal is available at www.accp.com/membership/nominations.aspx.

DEADLINES:

Due February 1, 2024 – Nominees’ supporting documents must be uploaded in the nominations portal for the fall 2024 awards (Robert M. Elenbaas Service, C. Edwin Webb Professional Advocacy, Russell R. Miller, Clinical Practice, and Education awards) and the 2025 elected offices.

Due February 15, 2024 – *Nominations* for the 2024 Parker Medal, the 2025 Therapeutic Frontiers Lecture, the 2024 “new” awards (New Investigator, New Clinical Practitioner, and New Educator), and the 2024 ACCP Fellows (FCCPs)

Due April 1, 2024 – Nominees’ supporting documents must be uploaded in the nominations portal for the 2024 “new” awards (New Investigator, New Clinical Practitioner, and New Educator) and the 2025 Therapeutic Frontiers Lecture

DESCRIPTIONS:

2024 ACCP Fellows: Fellowship is awarded in recognition of continued excellence in clinical pharmacy practice or research. Nominees must have been Full Members of ACCP for at least 5 years, must have been in practice for at least 10 years since receipt of their highest professional pharmacy degree, and must have made a sustained contribution to ACCP through activities such as presentation at College meetings; service to ACCP committees, PRNs, chapters, or publications; or election as an officer. Candidates must be nominated by any two Full Members other than the nominee, by any Fellow, or by any member of the Board of Regents. Current members of the Board of Regents, Foundation Board of Trustees, Pharmacotherapy Publications (PPI) Board of Directors, Credentials: Fellowship Committee, or ACCP staff are ineligible for consideration. **Nomination deadline: February 15, 2024.**

2024 Paul F. Parker Medal for Distinguished Service to the Profession of Pharmacy: Recognizes an

individual who has made outstanding and sustained contributions to improving or expanding the profession of pharmacy in an area of professional service – including, but not limited to, patient care, leadership, administration, finance, technology, information processing, service delivery, models of care, and advocacy. The award is not limited to pharmacists or ACCP members. Nominations must consist of a letter detailing the nominee’s qualifications for this award and his or her contributions to the profession of pharmacy; the nominee’s curriculum vitae, resume, or biographical sketch as available; and a minimum of three letters of recommendation. At least one of these letters must be from an individual outside the nominee’s current practice locale. Current members of the Board of Regents, Foundation Board of Trustees, PPI Board of Directors, Parker Medal Selection Committee, or ACCP staff are ineligible. **Nomination deadline: February 15, 2024, including supporting documents.**

2025 Therapeutic Frontiers Lecture Award:

Honors an internationally recognized scientist whose research is actively advancing the frontiers of pharmacotherapy. The recipient of this award is not required to be an ACCP member or a pharmacist. Nominations must include a letter of nomination from an ACCP member to the chair of the Awards Committee detailing the nominee’s qualifications for this award and their sustained contributions to pharmacotherapy, the nominee’s curriculum vitae, and a minimum of two letters of recommendation from other ACCP members. At least one of these letters must be from an individual outside the nominee’s current institute of practice. Current members of the Board of Regents, Foundation Board of Trustees, PPI Board of Directors, Awards Committee, or ACCP staff are ineligible. **Nomination deadline: February 15, 2024. Supporting documents are due April 1, 2024, as noted above.**

2024 New Investigator Award: This award highlights the research program of an ACCP member who has made a major impact on an aspect of clinical pharmaceutical science. Nominees must have been a Full Member of ACCP at the time of nomination and a member at any level for at least 3 years; they must have a research program with a significant publication record having a programmatic theme or an especially noteworthy single publication; and, at the time of nomination, it must have been within 6 years since completion of their terminal professional pharmacy

training or degree, whichever is most recent. If an individual pursues an additional degree beyond his or her professional pharmacy degree or training (i.e., Ph.D.), this additional degree will not be considered a terminal degree, and the 6-year time interval will extend from completion of the terminal pharmacy training or degree. Nominations will consist of a letter from an ACCP member to the chair of the Awards Committee detailing the nominee's qualifications for this award and the significance/impact of their research program, the nominee's curriculum vitae, and two letters of recommendation from other ACCP members. At least one of these letters must be from an individual outside the nominee's current institute of practice. Self-nominations are not permitted. Current members of the Board of Regents, Foundation Board of Trustees, PPI Board of Directors, Awards Committee, or ACCP staff are ineligible. **Nomination deadline: February 15, 2024. Supporting documents are due April 1, 2024, as noted above.**

2024 New Clinical Practitioner Award: This award recognizes a new clinical practitioner who has made outstanding contributions to the health of patients and/or the practice of clinical pharmacy. Nominees must have been Full Members of ACCP at the time of nomination and members at any level for at least 3 years. In addition, nominees must have completed their terminal professional pharmacy training or degree (whichever is most recent) within 6 years from the time of nomination. If an individual pursues an additional degree beyond his or her professional pharmacy degree or training (i.e., Ph.D.), this additional degree will not be considered a terminal degree, and the 6-year time interval will extend from completion of the terminal pharmacy training or degree. Fellows of ACCP (i.e., "FCCPs") are ineligible. Nominations will consist of a letter from an ACCP member to the chair of the Awards Committee detailing the nominee's qualifications for this award and the significance/impact of their clinical contributions,

the nominee's curriculum vitae, and two letters of recommendation from other ACCP members. At least one of these letters must be from an individual outside the nominee's current institute of practice. Self-nominations are not permitted. Current members of the Board of Regents, Foundation Board of Trustees, PPI Board of Directors, Awards Committee, or ACCP staff are ineligible. **Nomination deadline: February 15, 2024. Supporting documents are due April 1, 2024, as noted above.**

2024 New Educator Award: This award recognizes and honors a new educator for outstanding contributions to the discipline of teaching and to the education of health care practitioners. Nominees must have been Full Members of ACCP at the time of nomination and members at any level for at least 3 years. In addition, nominees must have completed their terminal professional pharmacy training or degree (whichever is most recent) within 6 years from the time of nomination. If an individual pursues an additional degree beyond his or her professional pharmacy degree or training (i.e., Ph.D.), this additional degree will not be considered a terminal degree, and the 6-year time interval will extend from completion of the terminal pharmacy training or degree. Fellows of ACCP (i.e., "FCCPs") are ineligible. Nominations will consist of a letter from an ACCP member to the chair of the Awards Committee detailing the nominee's qualifications for this award and the significance/impact of their educational contributions, the nominee's curriculum vitae, and two letters of recommendation from other ACCP members. At least one of these letters must be from an individual outside the nominee's current institute of practice. Self-nominations are not permitted. Current members of the Board of Regents, Foundation Board of Trustees, PPI Board of Directors, Awards Committee, or ACCP staff are ineligible. **Nomination deadline: February 15, 2024. Supporting documents are due April 1, 2024, as noted above.**

ACCP/ASHP Live Board Review & Recertification Courses

March 7-9, 2024 / Dallas, Texas



2024 ACCP Virtual Poster Symposium: Call for Abstracts

Important Dates:

- **Submission Deadline**
 - March 25, 2024: Submission deadline for Original Research, Systematic Reviews/Meta-Analyses, Case Reports, Clinical Pharmacy Forum, and Advances in International Clinical Pharmacy Practice, Education, or Training abstracts
 - April 22, 2024: Submission deadline for Research-in-Progress abstracts (Students and Residents and Fellows)
- **Notification of Acceptance**
 - April 29, 2024: Authors will be notified of acceptance or declination no later than this date.

ACCP invites you to submit an abstract to be considered for presentation during the 2024 ACCP Virtual Poster Symposium (VPS), May 21 and 22, 2024. The VPS was launched in 2012 because travel, funding, and schedule conflicts often made it difficult for participants to attend a conference in person. ACCP continues to host the VPS as an alternative means for individuals to present their research and scholarship to peers and to engage in dialogue with colleagues.

All investigators in the field of clinical pharmacy and clinical pharmacology, ACCP members and nonmembers

alike, are invited to submit abstracts. There is a \$50 fee to submit an abstract.

The deadline to submit abstracts (EXCLUDING Research-in-Progress abstracts) is March 25, 2024. The deadline to submit abstracts in the Research-in-Progress category is April 22, 2024.

Posters will be on display May 19 through May 26 for asynchronous viewing and comment. In addition, two interactive sessions will be held on May 21 and May 22, when authors and their virtual posters will be available for real-time online question-and-answer interactions. The technology required for presenters and the post-viewing audience is minimal – a broadband internet connection and a current version of an internet browser.

What is the ACCP VPS?

The VPS involves the electronic submission of an abstract. If the abstract is accepted, a poster is created and saved in standard PDF format. The poster is made available for viewing by all attendees during the designated VPS dates. Virtual poster presenters will be virtually present (**EITHER** May 21 or May 22 from 7 p.m. to 9 p.m. [EDT]) through an online, real-time chat feature. Presenters also have the option to offer live Q&A via their preferred video/audio platform (e.g., Zoom, Teams, Google Meet) during their assigned poster session. Presenters will be able to discuss their findings with students, residents, fellows, seasoned practitioners, and even family and friends during the symposium. Of importance, attendance to the VPS is free. All are invited to attend – ACCP members, colleagues, friends, and family.

Journal of the American College of Clinical Pharmacy - Themed Issue

CALL FOR PAPERS
SUBMISSIONS DUE JULY 15, 2024

...

**CLINICAL PHARMACY PRACTICE,
EDUCATION, AND ADVOCACY IN
THE MANAGEMENT OF DIABETES**

Guest Editors
Jennifer N. Clements, Pharm.D., FCCP
Christie A. Schumacher, Pharm.D., FCCP

All abstracts accepted for presentation, except for “Encore” and “Research-in-Progress” abstracts, will have full-text abstracts published online in *JACCP*. Only the abstract title, authors, and original citation will be published in *JACCP* for “Encore” presentations.

To review the complete submission instructions, guidelines, and review criteria, or to submit an abstract, visit <https://www.accp.com/abstracts/2024vps/>.

President’s Column

Turning It Up to 11 in 2024!



Brian Hemstreet, Pharm.D., FCCP, BCPS

Welcome to 2024! I hope you all had a restful holiday season and New Year’s Day. As we enter a new year, I always find it beneficial to reflect on the previous year’s activities and how they could influence the next 12 months. Certainly 2023 brought many great instances of ACCP members making a positive impact on the organization and the profession. This included their many contributions to ACCP task forces and committees, collaboration on national treatment guidelines, engagement in advocacy efforts, and outstanding research, practice, and educational accomplishments. I continue to be inspired by the amazing work of ACCP’s members and greatly appreciate their dedication to representing the College as leaders in clinical pharmacy.

Even as 2023 marked our substantial progress as an organization, it also highlighted the ongoing challenges facing both the profession and ACCP. Among these is the significant national impact of declining pharmacy school applications and admissions, which threatens to greatly reduce not only the number of graduates but also the number of future clinical pharmacists and potential ACCP members. Similarly, the concerns facing our community-based colleagues regarding the need to improve working conditions to provide safe and effective care have resulted in some pharmacists choosing to leave their workplace, further contributing to an altered public perception of pharmacy as a viable career pathway. Finally, even though interprofessional team-based care and collaboration is a standard we have long sought, ongoing concerns of non-pharmacy organizations regarding pharmacist scope of practice continue to present barriers to increasing patient access to clinical pharmacy services and establishing consistent compensation for these services.

Reflecting on these challenges has caused me, and perhaps many others, to question what’s next for the profession and how we as ACCP members can make a positive impact. During my incoming address at the 2023 ACCP Annual Meeting in Dallas, I shared my experience of fulfilling a personal goal of learning to play the guitar as a means of providing an outlet during the COVID-19 lockdown. Although it proved to be challenging, I’ve persevered and am happy to report that I am still engaged and continuing to practice on my guitar. Indeed, this foray into guitar-playing provided inspiration for my presidential theme this year, which is drawn from [This Is Spinal Tap](#). In this movie, the guitarist of the fictional band “Spinal Tap” uses an amplifier that can be set to a volume of 11 instead of the standard maximum of 10. By turning it up to 11, the guitarist can achieve a much louder sound, when needed. This phrase has become synonymous with going over and above the norm, and the Oxford English Dictionary even defines it as “[to reach or surpass the maximum level or limit.](#)”

Given the current state of our profession and the challenges facing us, I believe we are at a critical juncture where we need to look for opportunities to further amplify the voices of clinical pharmacists and continue to leverage the expertise and passion of ACCP’s members so as to ensure both the advancement of our essential roles on the health care team and the sustainability of our profession by fostering the development of the next generation of clinical pharmacists. These goals and enhancements are reflected in my presidential theme for this year: “*What’s Next for Clinical Pharmacy? Rising to the Challenges, Leading the Way, and Turning It Up to 11.*”

As we progress through 2024, my challenge to all ACCP members is to engage in whatever capacity you can and to look for opportunities to turn it “up to 11.” By doing so, we will continue to drive ACCP’s efforts to advance the profession and address future challenges. A key component of this approach will involve ensuring that ACCP members’ voices are heard. The ACCP Board of Regents will carry forward into 2024 the momentum generated at the end of 2023 by seeking and responding to member feedback. We will continue to provide opportunities for members to engage with ACCP leadership, and I look forward to your active participation and feedback. Thank you for the opportunity to serve as your president and for the excellent work you do on behalf of the College.

FIT/MeRIT Investigator Development Informational Calls Scheduled



The ACCP Foundation will host informational conference calls for anyone interested in learning more about the Foundation's programs for pharmacist-investigator development: Focused Investigator Training (FIT) and Mentored Research Investigator Training (MeRIT). The primary purpose of each conference call is to help familiarize potential applicants with each program's process and outcomes. Those interested in learning more about the FIT and MeRIT programs need to participate in only one of the informational calls scheduled for each desired program. Contact Sheldon Holstad (sholstad@accp.com) for videoconference information.

MeRIT informational conference calls:

- Monday, January 29, 2024: 4:00–4:30 p.m. (EST)
- Thursday, February 15, 2024: 1:00–1:30 p.m. (EST)

FIT informational conference calls:

- Monday, January 29, 2024: 5:00–5:30 p.m. (EST)
- Thursday, February 15, 2024: 2:00–2:30 p.m. (EST)

The FIT and MeRIT programs will be held concurrently June 3–7, 2024, on the campus of the University of Nebraska Medical Center, College of Pharmacy, in Omaha, Nebraska. Letters of intent to attend either program are due by February 28, and full applications are due by March 31, 2024. For an informational brochure or program application, visit accpfoundation.org/investigator.

Washington Report ACCP-PAC Election Year Outlook: Extending the Frontiers of Clinical Pharmacy Through Political Advocacy

*John McGlew
Director of Government Affairs*

ACCP-PAC is the political voice of the clinical pharmacy discipline. It is the only federal political action committee dedicated specifically to advancing the practice of clinical pharmacists and the care of their patients. In this pivotal presidential



election year, ACCP-PAC is active in its bipartisan support for members of Congress who will work to advance coverage for comprehensive clinical pharmacy services as an integrated Medicare benefit.

Through your support for ACCP-PAC, the College can attend fundraising events that provide a unique setting to educate representatives and senators about the essential work of clinical pharmacists in improving medication outcomes on behalf of patients.

About Senator Peter Welch



ACCP's Senior Director of Government Affairs, John McGlew (right) discusses Medicare payment reform efforts with Senator Welch at a 2022 Capitol Hill event.

Welch has served as the representative for Vermont's single congressional district since 2007 and [comfortably won](#) the 2022 U.S. Senate election in Vermont to succeed retiring Senator Patrick Leahy.

In the House of Representatives, Welch served on the Energy and Commerce Committee, where he was recognized as a leader on Medicare reform issues. He previously introduced the [Better Care, Lower Cost Act](#), aimed at improving care for chronically ill Medicare beneficiaries and reforming the fee-for-service system to facilitate team-based care that helps patients achieve their clinical goals.

In 2016, Welch hosted a congressional briefing on behalf of ACCP titled ["Getting the Medications Right": An Essential Ingredient in Achieving the Goals of H.R. 4878 – the Medicare Better Care, Lower Cost Act."](#) At the briefing, ACCP arranged for a pharmacist-physician panel to travel from Vermont to present on care delivery approaches to achieving medication optimization through formalized interprofessional practice structures composed of physicians and other health professionals providing direct patient care in collaboration with clinical pharmacists. This approach is recommended to Congress as essential for "getting the medications right" for patients, particularly those with complex and/or multiple chronic conditions and care needs.

Advancing Telehealth Legislation

In 2021, Welch, together with five other representatives, introduced the [Creating Opportunities Now for Necessary and Effective Care Technologies \(CONNECT\) for Health Act](#). This bipartisan and bicameral package aims to help expand access to important telehealth services that can lower health costs and make health care more efficient for patients. In introducing the legislation, Welch stated:

Underserved areas in both rural and urban communities desperately need cost-effective solutions to address the gap in health services. This bipartisan bill will bridge that gap by expanding telehealth to improve quality of care, increase access and reduce costs across America. This bill is a commonsense step to make sure that our policies keep pace with our technology.

About ACCP-PAC

ACCP's Political Action Committee (PAC) allows the College to participate in political campaign activities that strengthen its relationships with key policymakers on Capitol Hill. Providing financial support to influential leaders helps raise the profile of clinical pharmacy and demonstrates ACCP's ideological commitment to its core mission.

To maximize our impact, we must be strategic in targeting our limited resources on the health policy leaders best placed to advance our agenda. Here's how ACCP's leaders decide who should receive financial support.

Consistent with all of ACCP's initiatives, ACCP-PAC is member driven and is managed by a [Governing Council](#), which is responsible for decisions related to how PAC money is spent.

- ACCP-PAC is nonpartisan, committed to working with health policy leaders across all political parties and ideologies.
- ACCP-PAC supports candidates on the basis of their alignment with ACCP's mission to advance the profession and improve human health through research, training, and education.
- ACCP-PAC strategically targets members of Congress who sit on committees with jurisdiction over health care. In the Senate, ACCP-PAC primarily supports members on the Finance Committee and the Health, Education, Labor and Pensions (HELP) Committee. In the House, ACCP-PAC focuses on those who sit on the Ways and Means Committee and the Energy and Commerce Committee.

ACCP-PAC is committed to transparency – all contributions are reported to the [Federal Election Commission](#), and the information is available to the public.

Outlook for ACCP-PAC in 2024

Despite the well-documented political dysfunction in Washington, ongoing conversations with congressional leaders continue to demonstrate solid, fundamental support on Capitol Hill for the core policy driving ACCP's effort to establish Medicare coverage for clinical pharmacists' services that optimize medication use for patients.

Looking ahead to the remainder of the 118th Congress and the 2024 presidential election, ACCP has an opportunity to raise its profile on Capitol Hill by providing financial support for policymakers who work with the College to advance its issues. It is vital that ACCP provide support for its friends in Congress so that these leaders remain in Washington to advance policies that meaningfully address the health care issues the nation currently faces.

PAC contributions are a constitutionally protected part of the U.S. political system under the First Amendment's guarantee of free speech. ACCP-PAC is the only means through which the College can provide financial support for candidates for Congress. With its almost 17,000 members, ACCP is in a position to become one of the most prominent pharmacy PACs in Washington. To do this, the College needs the widespread support of its members. If each ACCP member contributed just \$25, ACCP-PAC would raise over \$400,000. All ACCP members should consider contributing least \$25 to ACCP-PAC. [CLICK HERE](#) to support your PAC today!

Congratulations to the Winners of the 2023 ACCP-PAC PRN Challenge!

Thank you to everyone who participated in the 2023 Challenge! The winning PRNs will receive coveted preferential time slots for their business meetings at the 2024 ACCP Annual Meeting.

- Total Dollars Raised: Pediatrics PRN
- Percentage of Participating PRN Members: Perioperative Care PRN

ACCP Oncology Genomics Certificate Program Begins February 27

This unique certificate program blends interactive live online learning (via Zoom) with self-study programming to equip clinical pharmacists with the necessary skills to apply oncology genomics to practice. From February 27 through May 14, participants will acquire skills to interpret genomic reports, develop treatment plans on the basis of genomic data, interact with an interprofessional

molecular oncology team, and learn strategies for implementing a Molecular Tumor Board at their own institutions.

Expert faculty will lead weekly online sessions that provide foundational knowledge about somatic genomics, next-generation sequencing (NGS), and necessary tools for interpreting NGS reports to develop effective treatment plans. Faculty will delve into pertinent oncology specialty topics, including lung cancer genomics, gynecologic cancer genomics, and hematologic malignancies. Strategies for implementing a Molecular Tumor Board will be demonstrated together with exploration of related ethical, legal, and social issues for consideration. Participants will have the opportunity to join in facilitated discussions, receive mentorship to solidify learning, and gain practice through practice sessions and case-based presentations with peers. Self-study modules and exercises will reinforce program topics.

Registered participants who complete this program will receive a certificate of completion and 2.0 CEUs (20.0 contact hours).

	Registration Rates (Note: There will also be a separate nominal registration fee for Canvas LMS).
Members	\$390
Nonmembers	\$690

[Click here](#) to learn more about the learning objectives, program faculty, and scheduled activities and to register.

ACCP’s DEIA Progress Report

ACCP remains dedicated to creating and sustaining a culture of diversity, equity, inclusion, and accessibility (DEIA). The organization’s work on DEIA began in 2020, with the initial [2021 Strategic Diversity, Equity, and Inclusion Plan](#) published in September 2021 and the [2023 Strategic Diversity, Equity, Inclusion, and Accessibility Plan](#) in November 2023. Over the past 3 years, ACCP members have driven significant changes within the organization to enhance inclusion and increase representation. It is difficult for individual members to stay abreast of all the past and ongoing work in this area. For example, it is not uncommon for members to suggest a focused area for DEIA work, only to learn that past or ongoing work aligns with their recommendation. To be fully transparent, ACCP has created a central location for interested members to review a comprehensive and frequently updated progress report. This report includes all objectives from both DEIA plans, together with each objective’s status and relevant activities. It is available as an easily searchable Word document that

UPCOMING EVENTS & DEADLINES:

[MeRIT Informational Conference Call](#)

January 29, 2024
4:00-4:30 p.m. EST

[FIT Informational Conference Call](#)

January 29, 2024
5:00-5:30 p.m. EST

[Clinical Research Challenge \(CRC\) Registration Deadline](#)

February 7, 2024

[MeRIT Informational Conference Call](#)

February 15, 2024
1:00-1:30 p.m. EST

[FIT Informational Conference Call](#)

February 15, 2024
2:00-2:30 p.m. EST

[2024 ACCP/ASHP Board Review and Recertification Courses](#)

March 7-9, 2024
Westin Galleria Dallas - Dallas, TX

will be frequently updated throughout the year. View the report on the [DEIA webpage](#) or by clicking [here](#). If you have questions about or feedback on ACCP’s DEIA efforts, please share them with the 2024 DEIA Task Force by sending an email to DEIA@accp.com or through an alternative communication channel, if you prefer.

It is important to recognize and celebrate our progress as we remain engaged in our long-term commitment to this work. Early achievements that are focused on inclusion are an essential first step but may not be as apparent as longer-term goals to increase diversity in leadership. It is a delicate balance of urgency and patience as we approach this work with the excellence that ACCP is known for. ACCP is taking a systematic, evidence-based approach to DEIA plan development and implementation. Early success in achieving inclusion-focused objectives together with data derived from the DEIA member assessments supports optimism that we will be successful in enhancing diversity and representation across the organization in time.

The ACCP Foundation will host informational conference calls for anyone interested in learning more about the Foundation’s programs for pharmacist-investigator development: Focused Investigator Training (FIT) and Mentored Research Investigator Training (MeRIT). The

primary purpose of each conference call is to help familiarize potential applicants with each program's process and outcomes. Those interested in learning more about the FIT and MerIT programs need to participate in only one of the informational calls scheduled for each desired program. Contact Sheldon Holstad (sholstad@accp.com) for videoconference information.

2024 ACCP Clinical Research Challenge – Local Journal Club Examination Available



ACCP's innovative and unique competition offers teams of three pharmacy students the opportunity to participate in an online journal club and submit a clinical research proposal. For the 2024 Clinical Research Challenge, the team registration deadline is

February 7, 2024.

The competition is only open to pharmacy students pursuing their first professional pharmacy degree from an accredited institution, or one that has been granted candidate status, who are in the first 2 years of their first professional pharmacy degree program (P1 and P2 students for 4-year programs; P1 and P2 students for 3-year accelerated programs; and the first 2 professional years for 0- to 6-year or 0- to 7-year programs). Only one team per institution can enter the competition. Institutions with branch campuses, distance satellites, or more than one interested team are encouraged to conduct a local competition. ACCP provides a written examination for institutions to use as a basis for their local competition if they wish. This examination may be requested by the ACCP faculty liaison or registering faculty member by email. Please address your email request to Michelle Kucera, Pharm.D., BCPS, at mkucera@accp.com.

Students are not required to be members of ACCP to participate. Team registration should be submitted [online](#) and must be initiated by a current faculty member at the respective institution. Students interested in forming a team should contact their ACCP faculty liaison. The deadline to complete team registration and confirm eligibility for the 2024 competition is **February 7, 2024**. For additional competition information, including the schedule, FAQs, and sample questions, click [here](#).

2024 FCCP Nominations Due February 15

Are you planning to nominate a colleague for 2024 Fellowship in the American College of Clinical Pharmacy (FCCP)? Fellowship in ACCP recognizes excellence in the practice and science of clinical pharmacy and is awarded to individuals who have made sustained contributions to the College and demonstrated exceptional performance in clinical pharmacy practice and/or research.

To be considered for Fellowship, candidates must be nominated by any of the following: two Full Members

of ACCP, one Fellow of ACCP, or a member of the Board of Regents. Separate letters of recommendation are not required or considered in the evaluation process. Nominees for FCCP must (1) be Full Members of ACCP for at least 5 years, (2) have been in practice for at least 10 years since receipt of their highest professional pharmacy degree (Pharm.D. or B.S.), and (3) have made sustained contributions to ACCP.

Once the nomination period closes, eligible nominees receive email notification of their nomination and are asked to submit the necessary application materials to be considered for recognition as a Fellow. Completed applications are reviewed by the Credentials: Fellowship Committee and are subsequently submitted for approval by the ACCP Board of Regents.

After nomination by their colleagues, Fellow candidates undergo a comprehensive evaluation of their service to the College and their practice and research accomplishments. Persons nominated as a Fellow must have made a substantial contribution to ACCP through activities such as presentations at College-sponsored meetings; service as a reviewer for ACCP, *Pharmacotherapy*, or the ACCP Foundation; contributions to College publications; service as a committee member; or contributions as a Practice and Research Network chair, chapter officer, or elected ACCP officer or regent. Practice and research criteria evaluated by the committee include examples of patient care service or educational programs developed by the nominee; certifications or other credentials earned; drug therapy management responsibilities; educational presentations; consultantships; service to publications; original research presentations, projects, funding, and publications; and other professional activities and awards.

Newly elected Fellows are inducted during the College's Annual Meeting Awards Ceremony and recognized at the Annual Fellows Dinner. Fellows may be recognized by the initials "FCCP" as part of their title as long as they are ACCP members in good standing.

Nominations for FCCP are submitted online at www.accp.com/membership/nominations.aspx. The deadline for submission of 2024 nominations is February 15. For more information about nominating or becoming a Fellow of ACCP, email membership@accp.com.

Member Recruiters

Many thanks to the following individuals for recruiting colleagues to join them as ACCP members:

Kyle Bierman	Tara Mains
Judy Chen	Austin Mathew
Leigh Keeton	Hasan McDonnaugh
Anas Khaleel	Sara Shahdoost
Robert MacLaren	Moghadam
Samantha Maina	Deidra Simpson

ACCP Career Center



The place for clinical
pharmacy careers.



Featured Positions

Title: Oncology Pharmacist
Employer: Salish Cancer Center
Location: Fife, Washington

[Learn More](#)

Title: Internal Medicine & Cardiology Pharmacy Specialist Positions
Employer: WVU Medicine - WVU Hospitals
Location: Morgantown, West Virginia

[Learn More](#)

Title: Assistant/Associate Professor - Ambulatory Care
Employer: Western University of Health Sciences, College of Pharmacy
Location: Pomona, California

[Learn More](#)

Title: Gary and Sharon Van Riper Scholar of Pharmacy Practice and Innovation (Faculty Position)
Employer: South Dakota State University College of Pharmacy and Allied Health Professions
Location: Sioux Falls, South Dakota

[Learn More](#)

Title: Clinical Assistant/Associate Professor of Pharmacy Practice
Employer: The University of Texas at El Paso School of Pharmacy
Location: El Paso, Texas

[Learn More](#)

Title: Critical Care Clinical Pharmacy Specialist
Employer: Orlando Health Orlando Regional Medical Center
Location: Orlando, Florida

[Learn More](#)

Title: Faculty Member, Ambulatory Care
Employer: St Johns University College of Pharmacy and Health Sciences
Location: Queens County, New York

[Learn More](#)

Title: Pharmacy Clinical Specialist - Immunocompromised Infectious Disease
Employer: Cleveland Clinic
Location: Cleveland, Ohio

[Learn More](#)

ACCP Career Center



The place for clinical
pharmacy careers.



Featured Positions

Title: Pharmacy Residency Program Director
Employer: SSM Health St. Anthony Hospital
Location: Oklahoma City, Oklahoma

[Learn More](#)

Title: Assistant/Associate Professor, Population Health and Primary Care Department of Clinical Pharmacy
Employer: University of Colorado Anschutz Medical Campus
Location: Aurora, Colorado

[Learn More](#)

Title: Clinical Pharmacist at Pottstown Hospital
Employer: Reading Hospital – Tower Health
Location: Pottstown, Pennsylvania

[Learn More](#)

Title: Director of Clinical Pharmacy Services
Employer: Legacy Community Health
Location: Houston, Texas

[Learn More](#)

Title: Internal Medicine and Transplant Clinical Pharmacy Specialist Positions
Employer: UofL Health
Location: Louisville, Kentucky

[Learn More](#)

Title: Clinical Pharmacists
Employer: McLeod Health
Location: Florence, South Carolina

[Learn More](#)

Title: Department Chair and Professor
Employer: University of Pittsburgh
Location: Pittsburgh, Pennsylvania

[Learn More](#)

Title: Clinical Faculty
Employer: University of Nebraska Medical Center College of Pharmacy
Location: Omaha, Nebraska

[Learn More](#)

ACCP Career Center



The place for clinical
pharmacy careers.



Featured Positions

Title: Associate Dean for Professional Pharmacy Education & Associate
or Full Professor

Employer: University of Washington

Location: Seattle, Washington

[Learn More](#)

Title: Clinical Pharmacist, Advanced Heart Failure/Cardiology

Employer: Wake Forest Baptist Medical Center

Location: Winston-Salem, North Carolina

[Learn More](#)